Abstract 1216P
Background
Employing a rapid liquid biopsy platform that can support clinicians in the diagnosis of different cancers, particularly for patients who develop cancers not targeted in current screening programs, would cause a paradigm shift in cancer diagnostics. Current liquid biopsies focus on single tumor derived biomarkers, such as circulating tumor DNA (ctDNA), which limits test sensitivity, especially for early-stage cancers that do not shed enough genetic material.
Methods
The Dxcover® Cancer Liquid Biopsy has been assessed upon its ability to predict individual cancers in organ-specific classifications: brain, breast, colorectal, kidney, lung, ovarian, pancreatic, and prostate cancer. The test uses Fourier transform infrared (FTIR) spectroscopy to build spectral profiles of serum samples, and machine learning algorithms to predict disease status. We also made a further exploratory evaluation of the ability to differentiate the signature from any one of the 8 cancers from non-cancer patient samples. We assessed the test performance when the cancer samples were grouped together to mimic patients with non-specific symptoms where the cancer site was uncertain. Additionally, we have examined non-generative data augmentation methods to improve machine learning performance.
Results
Area under the receiver operating characteristic curve (AUROC) values were calculated for 8 cancer types v symptomatic non-cancer controls: most classifiers achieved AUROC values above 0.85. The cancer v asymptomatic non-cancer classification detected 64% of stage I cancers when specificity was 99% (overall sensitivity 57%). When tuned for higher sensitivity, this model identified 99% of stage I cancers (with specificity 59%). For the colorectal cancer dataset, data augmentation using a WGAN led to an increase in AUROC from 0.91 to 0.96, demonstrating the impact data augmentation can have on deep learning performance, which could be useful when the amount of real data available for model training is limited.
Conclusions
This spectroscopic blood test can effectively detect early-stage cancer, and could facilitate the requisite earlier diagnosis when treatment can be more effective.
Clinical trial identification
Legal entity responsible for the study
Dxcover Limited.
Funding
Dxcover Limited.
Disclosure
M.J. Baker: Financial Interests, Personal, Full or part-time Employment: Dxcover Limited; Financial Interests, Personal, Leadership Role: Dxcover Limited; Financial Interests, Personal, Stocks or ownership: Dxcover Limited. J.M. Cameron, A. Sala, G. Antoniou, J.J.A. Conn, R.G. McHardy: Financial Interests, Personal, Full or part-time Employment: Dxcover Limited. D.S. Palmer: Financial Interests, Personal, Research Funding, Dxcover, GSK, Endophotonics: Dxcover Limited; Financial Interests, Personal, Stocks or ownership: Dxcover Limited; Financial Interests, Personal, Leadership Role: Dxcover Limited; Financial Interests, Personal, Full or part-time Employment: Dxcover Limited; Financial Interests, Personal, Advisory Role: Dxcover Limited.
Resources from the same session
1816P - Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
Presenter: Bertrand Tombal
Session: Poster session 14
1817P - A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care
Presenter: Elan Diamond
Session: Poster session 14
1818P - Final results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC)
Presenter: Kim van der Zande
Session: Poster session 14
1819P - PSMA-BAT: Prospective biomarker trial of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) undergoing bipolar androgen therapy (BAT)
Presenter: Aline Lara Gongora
Session: Poster session 14